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The past decade has witnessed major strides in theprevention of coronary heart disease (CHD) through
modification of its causes. The most dramatic advance has
been the demonstration that aggressive medical therapy will
substantially reduce the likelihood of recurrent major coro-
nary syndromes in patients with established CHD (secondary
prevention). The American Heart Association (AHA) and the
American College of Cardiology (ACC) have published joint
recommendations for medical intervention in patients with
CHD and other forms of atherosclerotic disease (1). A similar
potential exists for risk reduction in patients without estab-
lished CHD (primary prevention). However, the risk status of
persons without CHD varies greatly, and this variability
mandates a range in the intensity of interventions. Effective
primary prevention thus requires an assessment of risk to
categorize patients for selection of appropriate interventions.
The present statement is being published jointly by the AHA
and ACC to outline current issues and approaches to global
risk assessment for primary prevention. The approaches
described in this statement can be used for guidance at several
levels of primary prevention; however, the statement does not
attempt to specifically link risk assessment to treatment
guidelines for particular risk factors. Nonetheless, it provides
critical background information that can be used in the
development of new treatment guidelines.
The major and independent risk factors for CHD are
cigarette smoking of any amount, elevated blood pressure,
elevated serum total cholesterol and low-density lipoprotein
cholesterol (LDL-C), low serum high-density lipoprotein
cholesterol (HDL-C), diabetes mellitus, and advancing age
(Table 1). The quantitative relationship between these risk
factors and CHD risk has been elucidated by the Framingham
Heart Study (2) and other studies. These studies (2) show that
the major risk factors are additive in predictive power.
Accordingly, the total risk of a person can be estimated by a
summing of the risk imparted by each of the major risk
factors. Other factors are associated with increased risk for
CHD (Table 2). These are of 2 types: conditional risk factors
and predisposing risk factors. The conditional risk factors are
associated with increased risk for CHD, although their
causative, independent, and quantitative contributions to
CHD have not been well documented. The predisposing risk
factors are those that worsen the independent risk factors.
Two of them—obesity and physical inactivity—are desig-
nated major risk factors by the AHA (3,4). The adverse
effects of obesity are worsened when it is expressed as
abdominal obesity (5), an indicator of insulin resistance.
Clinical Importance of Global Estimates for
CHD Risk
Preventive efforts should target each major risk factor. Any
major risk factor, if left untreated for many years, has the
potential to produce cardiovascular disease (CVD). Nonethe-
less, an assessment of total (global) risk based on the
summation of all major risk factors can be clinically useful
for 3 purposes: 1) identification of high-risk patients who
deserve immediate attention and intervention, 2) motivation
of patients to adhere to risk-reduction therapies, and 3) mod-
ification of intensity of risk-reduction efforts based on the
total risk estimate. For the latter purpose, patients at high risk
because of multiple risk factors may require intensive mod-
ification of $1 risk factors to maximize risk reduction.
Guidelines for the management of individual risk factors are
provided by the second Adult Treatment Panel report (ATP
II) of the National Cholesterol Education Program (NCEP)
(6), the sixth report of the Joint National Committee (JNC
VI) of the National High Blood Pressure Education Program
(7), and the American Diabetes Association (ADA) (8). All of
these guidelines are currently endorsed or supported by the
AHA and the ACC. These reports (6–8) advocate adjusting
the intensity of risk factor management to the global risk of
the patient. In ATP II and JNC VI (6,7), overall risk is
estimated by adding the categorical risk factors. They do not
use a total risk estimate based on summation of risk factors
that have been graded according to severity; this latter
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approach has been advocated recently by Framingham inves-
tigators (2). The use of categorical risk factors has the
advantage of simplicity but may be lacking in some of the
accuracy provided by graded risk factors.
Some researchers and clinicians believe that the summa-
tion of graded risk factors provides advantages over the
addition of categorical risk factors. For instance, the use of
graded risk factors has been recommended in risk-
management guidelines developed by joint European societ-
ies in cardiovascular and related fields (9). Advocates of this
approach contend that the increased accuracy provided by the
grading of risk factors outweighs the increased complexity of
the scoring procedures. If the Framingham system is to be
used, however, its limitations as well as its strengths must be
understood. The AHA’s Task Force on Risk Reduction
recently issued a scientific statement (10) that reviewed and
assessed the utility of Framingham scoring as a guide to
primary prevention. The present report expands on this
assessment and considers factors that must be taken into
account when the Framingham algorithm is used (2).
Primary Versus Secondary Prevention
The present report focuses mainly on risk assessment for
coronary disease and not on risk for other cardiovascular
outcomes. Framingham scores estimate risk for persons
without clinical manifestations of CHD (2). Therefore, the
scores apply only to primary prevention, ie, to prevention in
persons without established CHD. Once coronary atheroscle-
rotic disease becomes clinically manifest, the risk for future
coronary events is much higher than that for patients without
CHD (6), regardless of other risk factors, and in this case,
Framingham scoring no longer applies. The AHA and ACC
have issued joint guidelines for the management of risk
factors for patients with established CHD and other forms of
atherosclerotic disease (1).
Definition of CHD
Interpretation of risk estimates for CHD requires a precise
definition of CHD. Framingham estimates traditionally pre-
dict total CHD, which includes angina pectoris, recognized
and unrecognized myocardial infarction, coronary insuffi-
ciency (unstable angina), and CHD deaths. In contrast, many
clinical trials (11–14) that have evaluated specific risk-
reducing therapies have specified major coronary events
(recognized acute myocardial infarction and CHD deaths) as
the primary coronary end points. In accord, the recent
Framingham report (2) also provided estimates for “hard”
CHD, excluding angina pectoris. The inclusion of coronary
insufficiency (unstable angina) and unrecognized myocardial
infarction (defined by electrocardiography) probably gives
estimates of hard CHD that are somewhat higher than
combined end points reported in several clinical trials (11–14). A
recent clinical trial, the Air Force/Texas Coronary Artery Pre-
vention Study (AFCAPS/TexCAPS) (15), specified acute coro-
nary events, including unstable angina, acute myocardial infarc-
tion, and coronary death, as the primary end point. This
combined end point probably corresponds closely to the Fra-
mingham study’s definition of hard CHD. Definitions of coro-
nary end points assume critical importance when risk cutpoints
are defined to select patients for specific therapies.
Absolute Risk Estimates
Absolute risk is defined as the probability of developing CHD
over a given time period. The recent Framingham report (2)
specifies absolute risk for CHD over the next 10 years.
Although absolute risk scores can be used to evaluate
preventive strategies, 4 caveats must be kept in mind. First,
Framingham scores derive from measurements made some
years ago; the possibility exists that absolute risk for any
given level of risk factors in the general population may have
changed since that time. Second, absolute risk in the Fra-
mingham population for any given set of risk factors may not
be the same as that for all other populations, for example,
those of differing ethnic characteristics. Third, Framingham
risk scores represent average values; however, considerable
individual variability in risk exists within the Framingham
population. For example, several other factors not included in
the Framingham scores potentially modify absolute risk for
individuals (see Table 2). Finally, Framingham scores are not
necessarily elastic; the magnitude of risk reduction achieved
by modifying each risk factor may not equal (in reverse) the
increment in risk accompanying the factors.
TABLE 1. Major Independent Risk Factors
Cigarette smoking
Elevated blood pressure
Elevated serum total (and LDL) cholesterol
Low serum HDL cholesterol
Diabetes mellitus
Advancing age
TABLE 2. Other Risk Factors
Predisposing risk factors
Obesity*†
Abdominal obesity†
Physical inactivity*
Family history of premature coronary heart disease
Ethnic characteristics
Psychosocial factors
Conditional risk factors
Elevated serum triglycerides
Small LDL particles
Elevated serum homocysteine
Elevated serum lipoprotein(a)
Prothrombotic factors (eg, fibrinogen)
Inflammatory markers (eg, C-reactive protein)
*These risk factors are defined as major risk factors by the AHA (3,4).
†Body weights are currently defined according to BMI as follows: normal
weight 18.5–24.9 kg/m2; overweight 25–29 kg/m2; obesity .30.0 kg/m2
(obesity class I 30.0–34.9, class II 35.9–39.9, class III $50 kg/m2). Abdominal
obesity is defined according to waist circumference: men .102 cm (.40 in)
and women .88 cm (35 in) (5).
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Definition of Low Risk
The Framingham report (2) defined low risk as the risk for
CHD at any age that is conferred by a combination of all the
following parameters: blood pressure ,120/,80 mm Hg,
total cholesterol 160 to 199 mg/dL (or LDL-C 100 to 129
mg/dL), and HDL-C $45 mg/dL for men or $55 mg/dL for
women in a nonsmoking person with no diabetes (Table 3).
This definition of low risk seems appropriate and should be
widely applicable; for example, in the follow-up of 350 000
screenees of the Multiple Risk Factor Intervention Trial (16),
most of the excess mortality from CHD could be explained by
the presence of the major risk factors above these levels. The
NCEP (6) designated a total cholesterol level of ,200 mg/dL
(or LDL-C of ,130 mg/dL) as a desirable level. Framingham
investigators (2) included total cholesterol levels in the range
of 160 to 199 mg/dL (and LDL-C of 100 to 129 mg/dL) in
their definition of the low-risk state. In addition, NCEP (6)
recognized an LDL-C level of #100 mg/dL as optimal and as
the goal of therapy for secondary prevention. This level
corresponds to a total cholesterol level of ’,160 mg/dL. An
elevated LDL-C level appears to be the primary CHD risk
factor, because some elevation of LDL seems to be necessary
for the development of coronary atherosclerosis (17). A
very-low-risk state can be defined as an LDL-C level of ,100
mg/dL in the presence of other low-risk parameters (Table 3).
Therapeutic efforts to reestablish a very-low-risk state appear
to be justified for secondary prevention (1,6); in primary
prevention, however, a very low LDL-C level is not currently
deemed necessary (6).
Relative Risk Versus Absolute Risk:
Estimations From Framingham Scores
The relative risk is the ratio of the absolute risk of a given
patient (or group) to that of a low-risk group. Literally, the
term relative risk represents the ratio of the incidence in the
exposed population divided by the incidence in unexposed
persons. The denominator of the ratio can be either the
average risk of the entire population or the risk of a group
devoid of risk factors. The Framingham definition of the
low-risk state provides a useful denominator to determine the
effect of risk factors on a patient’s risk. Both the absolute and
relative risk can be derived from the recently published risk
score sheets (2).
The first step in estimating risk is to calculate the number
of Framingham points for each risk factor (Table 4). For
initial assessment, measurements of serum levels of total
cholesterol (or LDL-C) and HDL-C are required (2). The
points for total cholesterol instead of LDL-C are listed in
Table 4 because some of the Framingham database did not
include LDL-C. Hence, total cholesterol gives more robust
estimates. Evaluation for cholesterol disorders requires mea-
surement of LDL-C, which is also the primary target of
cholesterol-lowering therapy (6). The blood pressure value
used in scoring is that obtained at the time of assessment,
regardless of whether the patient is taking antihypertensive
TABLE 3. Definition of a Low-Risk State*
Serum total cholesterol 160 to 199 mg/dL
LDL-C 100 to 129 mg/dL
HDL-C $45 mg/dL in men and $55 mg/dL in women
Blood pressure ,120 mm Hg systolic and ,80 mm Hg diastolic
Nonsmoker
No diabetes mellitus
*According to Framingham Heart Study (2).
TABLE 4. Global Risk Assessment Scoring
Risk Factor
Risk Points
Men Women
Age, y
,34 21 29
35–39 0 24
40–44 1 0
45–49 2 3
50–54 3 6
55–59 4 7
60–64 5 8
65–69 6 8
70–74 7 8
Total cholesterol, mg/dL
,160 23 22
169–199 0 0
200–239 1 1
240–279 2 2
$280 3 3
HDL cholesterol, mg/dL
,35 2 5
35–44 1 2
45–49 0 1
50–59 0 0
$60 22 23
Systolic blood pressure, mm Hg
,120 0 23
120–129 0 0
130–139 1 1
140–159 2 2
.160 3 3
Diabetes
No 0 0
Yes 2 4
Smoker
No 0 0
Yes 2 2
Adding up the points
Age
Cholesterol
HDL-C
Blood pressure
Diabetes
Smoker
Total points
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drugs. The average of several blood pressure measurements is
needed for an accurate determination of the baseline level.
Finally, in the present report, Framingham risk scores for
borderline elevations have been modified to assign stepwise
incremental risk in accord with current NCEP (6) and JNC VI
(7) guidelines. Failure of Framingham scores to identify
stepwise increments in risk in borderline zones probably
reflects the relatively small size of the Framingham cohort.
Diabetes is defined as a fasting plasma glucose level .126
mg/dL, to conform with recent ADA guidelines (18); in the
Framingham study, diabetes was defined as a fasting glucose
level .140 mg/dL. The designation of “smoker” indicates
any smoking in the past month. The total risk score sums the
points for each risk factor.
Risk ratios, relative to the low-risk state (Table 3), are
shown for men in Figure 1 and for women in Figure 2; for
each age, the number shown gives the relative risk. In
addition, 10-year absolute risk values are shown for both total
and hard CHD. The definition of hard CHD is that used by
Framingham investigators; values shown for hard CHD are
approximately two thirds those for total CHD, which are in
accord with the recent Framingham report (2). Gradations of
increasing relative risk are given in color. At the midpoint of
this gradation is the average risk for the Framingham cohort
for each age range. Ratios above average are divided into
moderately high relative risk and high relative risk. A 3-fold
increase in relative risk above the lowest risk level is
designated moderately high risk; a 4-fold or greater increase
is called high risk. Absolute risk levels rise progressively with
age, even in the absence of risk factors.
Relative risk is useful for providing the physician with an
immediate perspective of a patient’s overall risk status
relative to a low-risk state. This perspective can be helpful as
a frame of reference for both physician and patient. More-
over, relative risk probably can be used to compare risk
among individuals in populations in which baseline absolute
risk has not been established. Absolute baseline risk (low-risk
level) almost certainly varies among different populations,
but the relative contributions of individual risk factors to total
risk appear to be similar among all populations. Although the
comparability of relative risk has not been proven rigorously,
examination of available data from different epidemiological
studies (19–28) suggests this to be the case.
It is apparent from Figures 1 and 2 that the relative risk
associated with a given set of risk factor levels (expressed as
a single Framingham number) declines with advancing age.
At the same time, 10-year absolute risk rises with aging. Both
changes have implications for prevention. Higher relative risk
estimates in young adults are an indication of the high
long-term risk accompanying the risk factors; they point to
the need to institute a long-term risk-reduction strategy. On
the other hand, the increasing absolute risk that accompanies
advancing age reveals the opportunity for reducing absolute
short-term risk by an immediate aggressive reduction of risk
factors in older people. However, the best candidates for
aggressive risk reduction among older patients may be
those with moderately high or high relative risk. Recent
guidelines have emphasized absolute risk estimates for use
in treatment guidelines. Even so, the utility of relative risk
estimates for areas of primary prevention that are most
contentious, specifically, in young adults and elderly
patients, should not be overlooked in the development of
future guidelines.
Figure 1. Relative and absolute risk estimates for
CHD in men as determined for Framingham scor-
ing (2). The number of Framingham points is
derived as shown in Table 4. Relative risk esti-
mates for each age range are compared with
baseline risk conferred by age alone (in the
absence of other major risk factors). Relative risk is
graded and color coded to include below average,
average, moderately above average, and high-risk
categories. Distinctions in relative risk are arbitrary.
Average risk refers to that observed in the Fra-
mingham population. Absolute risk estimates are
given in the 2 right-hand columns. Absolute risk is
expressed as the percentage likelihood of develop-
ing CHD per decade. Total CHD risk equates to all
forms of clinical CHD, whereas hard CHD includes
clinical evidence of myocardial infarction and coro-
nary death. Hard CHD estimates are approximated
from the published Framingham data (2).
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Absolute Short-Term Risk
Estimates of short-term risk (absolute risk in the next 10
years) are potentially useful for the identification of patients
who need aggressive risk reduction in the clinical setting.
Patients at high short-term risk may need pharmacological
agents to control risk factors. The precise level of absolute
risk that defines a patient at high short-term risk has been an
issue of some uncertainty and involves a value judgment.
Theoretically, this level of risk justifies aggressive risk-
reduction intervention and is set through an appropriate
balancing of efficacy, costs, and safety of therapy. Over time
and depending on economic considerations, the thinking
about this critical cutpoint of risk may change. Furthermore,
little dialogue has occurred in the United States regarding the
process of choosing a single absolute risk cutpoint for high
short-term risk. The NCEP has taken the lead in adjusting the
aggressiveness of cholesterol-lowering therapy to the abso-
lute risk of patients. The NCEP identified patients having
established CHD and other atherosclerotic disease as being at
very high risk and deserving of aggressive therapy. For
primary prevention, LDL-C goals were established by count-
ing risk factors, but they did not define absolute risk in
precise, quantitative terms. Future guidelines for risk reduc-
tion in the United States likely will put greater emphasis on
quantitative global risk assessment.
Recently, guidelines of the joint European Societies (9)
have identified high short-term risk as an absolute risk that
imparts a .20% probability of developing CHD in the next
10 years. Once a patient reaches this threshold of risk,
guidelines similar to those for secondary prevention are
triggered. This threshold may be reasonable, but several
comments must be made about how the European guidelines
were derived. The authors (9) made use of older Framingham
risk equations, (29) but their own risk estimates were based
only on age, cigarette smoking, blood pressure, and total
cholesterol. HDL-C levels were not included. Framingham
risk equations (2,29) consistently include HDL-C, which is a
powerful independent risk factor. The absence of HDL-C as
a risk factor in European guidelines must be considered a
limitation. As previously mentioned, European guidelines (9)
used Framingham’s total CHD as the coronary end point, which
is a liberal coronary outcome and lowers the barrier to initiation
of secondary-prevention guidelines. Irrespective of these details,
there appears to be considerable consensus in the European
cardiovascular community that a 10-year risk for clinical coro-
nary end points of .20% justifies the category of high short-
term risk. One concern about European guidelines is that
although they creatively bridge the gap between primary and
secondary prevention, they seemingly deemphasize the need for
long-term primary prevention in the clinical setting.
Figure 2. Relative and absolute risk estimates for
CHD in women as determined for Framingham
scoring (2). The number of Framingham points is
derived as shown in Table 4. Relative risk esti-
mates for each age range are compared with
baseline risk conferred by age alone (in the
absence of other major risk factors). Relative risk is
graded and color coded to include below average,
average, moderately above average, and high-risk
categories. Distinctions in relative risk are arbitrary.
Average risk refers to that observed in the Fra-
mingham population. Absolute risk estimates are
given in the 2 right-hand columns. Absolute risk is
expressed as the percentage likelihood of develop-
ing CHD per decade. Total CHD risk equates to all
forms of clinical CHD, whereas hard CHD includes
clinical evidence of myocardial infarction and coro-
nary death. Hard CHD estimates are approximated
from the published Framingham data (2).
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Absolute Long-Term Risk
Framingham scoring does not directly project long-term risk
(.10 years), although such risk can be approximated by the
summing of risk scores over successive age categories and
the subtraction of those persons removed by having CHD
events. Thus, 20-year risk should be at least twice the 10-year
risk. An important aim of primary prevention is to reduce
CHD over the long term and not just over the short term. For
a patient in the age range of 50 to 54 years, a 20-year
projection of absolute risk may be of more interest to both the
physician and the patient than a 10-year projection. Such a
patient whose 10-year risk for CHD is 15% may not qualify
as being at high short-term risk, but this same patient has a
.30% probability of developing CHD before age 75. This
latter projection needs to considered when primary preven-
tion strategies are planned.
Another critical point to make about long-term risk is that
any single coronary risk factor, eg, cigarette smoking, hyper-
tension, high serum cholesterol, or diabetes, can lead to
premature CHD (or stroke) if left untreated over a period of
many years. Therefore, each of the major risk factors deserves
intervention in the clinical setting, regardless of the short-
term absolute risk. The centerpiece of long-term risk reduc-
tion is modification of lifestyle habits, eg, smoking cessation,
change in diet composition, weight control, and physical
activity (30). Nonetheless, in patients in whom long-term risk
is high, the use of drugs for treatment of hypertension or
serum cholesterol disorders may be warranted, as described in
JNC VI (7) and ATP II (6), respectively.
Severity of Major Risk Factors
Framingham scoring takes into account gradations in risk
factors when estimating absolute risk. The scoring does not
adequately account for severe abnormalities of risk factors,
eg, severe hypertension, severe hypercholesterolemia, or
heavy cigarette smoking. In such cases, Framingham scores
can underestimate absolute risk. This underestimation is
particularly evident when only 1 severe risk factor is present.
Thus, heavy smoking (31) or severe hypercholesterolemia
(32) can lead to premature CHD even when the summed score
for absolute risk is not high. Likewise, the many dangers of
prolonged, uncontrolled hypertension are well known. These
dangers underscore the need to control severe risk factors
regardless of absolute short-term risk estimates.
Diabetes Mellitus as a Special Case in
Risk Assessment
That diabetes mellitus is a major risk factor for CVD is well
established (2). Both type 1 diabetes (33) and type 2 diabetes
(34) confer a heightened risk for CVD. Type 2 diabetes is of
particular concern because it is so common and usually
occurs in persons of advancing age, when multiple other risk
factors coexist. There is a growing consensus that most
patients with diabetes mellitus, especially those with type 2
diabetes, belong in a category of high short-term risk. When
the risk factors of diabetic patients are summed, their risk
often approaches that of patients with established CHD (35).
The absolute risk of patients with type 2 diabetes usually
exceeds the Framingham score for hyperglycemia because
other risk factors almost always coexist. Another reason to
elevate the patient with diabetes to a higher risk category than
suggested by Framingham scoring is the poor prognosis of
these patients once they develop CHD (36). These factors
point to the need to intensify the management of coexisting
risk factors in patients with diabetes (7,37). These consider-
ations about the very high risk of patients with diabetes apply
to ethnic groups that have a relatively high population risk for
CHD. The inclusion of patients with type 2 diabetes in the
very-high-risk category may not be appropriate when they
belong to ethnic groups with a low population risk.
Absolute Risk Assessment in Elderly Patients
One of the more prominent features of the Framingham risk
scoring is the progressive increase in absolute risk with
advancing age (Figures 1 and 2). This increase undoubtedly
reflects the cumulative nature of atherogenesis. With advanc-
ing age, people typically accumulate increasing amounts of
coronary atherosclerosis. This increased plaque burden itself
becomes a risk factor for future coronary events (38–40).
Framingham scoring for age reflects this impact of plaque
burden on risk. Still, average scores mask the extent of
variability in plaque burden in the general population. To
apply average risk scores for age to individual patients may
lead to miscalculation of true risk, particularly because
Framingham applies so much weight to age as a risk factor.
Miscalculation of risk could lead to inappropriate selection of
patients for aggressive risk-reduction therapies. This fact
points to the need for flexibility in adapting treatment
guidelines to older persons. The tempering of treatment
recommendations with clinical judgment becomes increas-
ingly important with advancing age, particularly after the age
of 65. In the future, measures of subclinical atherosclerosis
may improve the accuracy of global risk assessment in older
patients. When risk scoring is used to adjust the intensity of
risk factor management in elderly patients, relative risk
estimates may be more useful than absolute risk estimates.
Relative risk estimates essentially eliminate the age factor
and are based entirely on the major risk factors. These
estimates allow the physician to stratify and compare patients
of the same age, and patients at highest relative risk could be
selected for the most aggressive risk management.
Certain Limitations of Framingham Database
Certain features of the Framingham scores reflect limitations
of the data set. For example, LDL-C and HDL-C levels are
known to be continuous in their correlation with CHD risk.
Presumably because of an insufficient number of subjects in
all categories, these continuous relationships are not consis-
tently observed between each incremental category (2).
Moreover, the assigned scores for each category are not
entirely consistent with the notations for graded risk proposed
by the NCEP (6) and the JNC (7). Framingham scores
probably require adjustment to account for the continuous
relationship between risk factors and CHD (6,7). As stated
previously, this adjustment was made in Table 4. Finally,
there is no indication that Framingham scoring has been
corrected for regression dilution bias (41); this bias results
from the random fluctuation of risk factors over time such
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that single measures of risk factors systematically underesti-
mate the association between risk factors and CHD.
Prediction scores from Framingham illustrate the substan-
tial difference in CHD risk between men and women before
age 70. The difference between men and women particularly
stands out for hard CHD end points. The diagnosis of angina
contributes a sizable fraction of all CHD end points in
middle-aged women and accounts for the notable difference
between total CHD and hard CHD in this age group.
Nonatherosclerotic anginal syndromes may have been misla-
beled among total CHD end points in some Framingham
women. The relatively small rise in risk for total CHD events
after age 55 should not obscure the progressive increase in
risk for hard CHD in older women. Framingham findings on
hard end points are more consistent with population studies
that show a sharp rise in CHD morbidity and mortality in
women after age 70. Even so, a discrepancy in CHD risk
between men and women persists throughout all age groups.
Use of Conditional and Predisposing Risk
Factors in Risk Assessment
In addition to the major risk factors (Table 1), a series of other
risk correlates have been identified (Table 2). Their presence
may denote greater risk than revealed from summation of the
major risk factors. Their quantitative contribution and inde-
pendence of contribution to risk, however, are not well
defined. Usually, therefore, they are not included in global
risk assessment. This does not mean that they do not make an
independent contribution to risk when they are present. A
sizable body of research supports an independent contribution
of each. Their relation to CHD is more complex than is that
of the major risk factors. In some cases, they are statistically
correlated with the major risk factors; hence, their own
independent contribution to CHD may be obscured by the
major risk factors. In other cases, their frequency in the
population may be too low for them to add significant
independent risk for the entire population; in spite of this,
they could be important causes of CHD in individual patients.
Several of the other risk factors represent direct targets of
therapy, either because they are causes of the major risk
factors or because circumstantial evidence of a role in
atherogenesis is relatively strong. Thus, even though these
other risk factors are not recommended for inclusion in
absolute risk assessment, their exclusion from this function
should not be taken to imply that they are clinically unim-
portant. Their role in evaluation and management of patients
at risk deserves some consideration.
Obesity
The AHA defines obesity as a major risk factor for CVD (42).
Risk is accentuated when obesity has a predominant abdom-
inal component (5). Obesity typically raises blood pressure
and cholesterol levels (42–44) and lowers HDL-C levels
(43,44). It predisposes to type 2 diabetes (5). It also adversely
affects other risk factors: triglycerides (43,44); small, dense
LDL particles (45); insulin resistance (46,47); and prothrom-
botic factors (48,49). Although not shown by the Framing-
ham data (2), other long-term longitudinal studies suggest
that obesity predicts CHD independently of known risk
factors. The association between excess body weight and
CHD seems particularly strong in white Americans. For
example, in one long-term prospective study (50), men aged
40 to 65 years with body mass index (BMI) 25 to 29 kg/m2
were 72% more likely to develop fatal or nonfatal CHD than
were men who were not overweight. In another study (51),
women whose BMI was 23 to 25 kg/m2 carried a 50%
increase in risk for CHD compared with women with lower
BMIs. The overall relation between body weight and CHD
morbidity and mortality is less well defined for Hispanics,
(52) Pima Indians (53), and black American women (54);
even so, obesity is a risk factor for type 2 diabetes, which
itself is a risk factor for CHD. Much remains to be learned
about the biological mechanisms underlying the association
between obesity and CHD, but without question, a strong
association exists. Consequently, obesity is a strong risk
factor for CHD (3) and is a direct target for intervention (5).
Prevention of obesity and weight reduction in overweight
persons are integral parts of the strategy for long-term risk
reduction. The recent report of the NHLBI Obesity Education
Initiative (5) provides a comprehensive guideline for the
management of overweight and obese patients in clinical
practice.
Physical Inactivity
The AHA also classifies physical inactivity as a major risk
factor. (4) Many investigations (55), including the Framing-
ham Heart Study (56–59), demonstrate that physical inactiv-
ity confers an increased risk for CHD. The extent to which
physical inactivity raises coronary risk independently of the
major risk factors is uncertain (60). Certainly, physical
inactivity has an adverse effect on several known risk factors
(60). Even though physical inactivity is an independent risk
factor, physical activity levels are difficult to reliably measure
in individual patients. For these reasons, physical inactivity is
not included in quantitative risk assessment. In spite of these
limitations in assessment, previous studies (61,62) document
that regular physical activity reduces risk for CHD. Physical
inactivity constitutes an independent target for intervention.
Physicians should encourage all of their patients to engage in
an appropriate exercise regimen, and high-risk patients
should be referred for professional guidance in exercise
training. The AHA recently published practical recommen-
dations for exercise regimens designed to reduce risk for
CVD (63).
Family History of Premature CHD
There is little doubt that a positive family history of prema-
ture CHD imparts incremental risk at any level of risk factors.
This association has been shown by the Framingham Heart
Study (64). Nonetheless, the degree of independence from
other risk factors and the absolute magnitude of incremental
risk remain uncertain. For this reason, Framingham investi-
gators did not include family history among the major
independent risk factors. The NCEP (6) counts a positive
family history of CHD as an independent risk factor that
modifies the intensity of LDL-lowering therapy. Regardless
of whether family history is used to modify risk management
in individual patients, the taking of a family history is
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undoubtedly important. A positive family history for prema-
ture CHD calls forth the need to test a patient’s relatives for
both premature CVD and the presence of risk factors.
Psychosocial Factors
There has long been an interest in the contribution of
personality and socioeconomic factors to CHD risk. Recently,
specific factors including hostility, depression, and social
isolation have been shown to have predictive value (65–67).
These factors, however, are not included in the Framingham
data and cannot be incorporated into the model currently.
Nonetheless, they might be taken into account in individual
patients when an overall strategy for risk reduction is being
developed.
Ethnic Characteristics
The Framingham population represents the world’s most
intensively studied population for cardiovascular risk factors.
This study is of great value in developing population-based
risk estimates in this population. Because Framingham resi-
dents are largely whites of European origin, it is uncertain
whether baseline absolute risk is similar to that in other
populations. Available evidence suggests that absolute risk
varies among different populations independently of the
major risk factors. For example, absolute risk among South
Asians (Indians and Pakistanis) living in Western society
appears to be about twice that of whites, even when the 2
populations are matched for major risk factors (68–70). This
higher baseline risk should be considered when South Asians
living in the United States are evaluated. Available compar-
isons of non-Hispanic white, non-Hispanic black, and His-
panic Americans (71,72) point to a comparable absolute risk
status, but large systematic comparisons are in the early
stages. It is also possible that some populations have a lower
baseline risk than the whites studied in Framingham. For
example, results of the Honolulu Heart Study (27) suggest
that Hawaiians of East Asian ancestry have only about two
thirds the absolute risk of Framingham subjects. In the Seven
Countries Study (73), the population of Japan exhibited a
much lower risk for CHD for a given set of risk factors than
other populations. Differences in absolute risk among differ-
ent demographic groups suggest the need for adjustments in
estimates of absolute risk from Framingham scores depend-
ing on racial and ethnic origins. Although absolute risk scores
may not be transportable to all populations, relative risk
estimates probably are reliable across groups. To date, com-
parison studies are insufficient to provide quantitative esti-
mates of the adjustments needed for Framingham scores
when they are applied to individuals from different demo-
graphic backgrounds. In spite of the limitations of the
Framingham data, absolute risk estimates as applied to some
populations seem applicable to the large populations of
non-Hispanic white, Hispanic, and black Americans in the
United States. For other groups, relative risk estimates still
seem applicable.
Hypertriglyceridemia
Framingham scoring does not ascribe independence to tri-
glyceride levels in risk assessment. Framingham investigators
(74) nonetheless have reported that elevated serum triglycer-
ides are an independent risk factor, as have other reports.
(75–77) Hypertriglyceridemia is correlated with other risk
factors (78); however, its degree of independent predictive
power is difficult to assess. Several clinical trials (79–81)
found that drugs that primarily affect triglyceride-rich li-
poproteins reduce CHD risk when used with patients with
hypertriglyceridemia. Elevated triglycerides consequently
may become a target of therapy independent of LDL lower-
ing. The reduction of serum triglyceride levels will also
decrease the concentrations of small LDL particles, another
putative risk factor (82,83). Of course, weight reduction in
overweight patients and adoption of regular exercise by
sedentary persons will lower triglyceride levels, which is one
way in which these changes in lifestyle reduce CHD risk.
Insulin resistance is another risk correlate for CHD (84,85).
The mechanisms of association between insulin resistance are
complex and likely multifactorial. Regardless, a large portion
of all patients who are candidates for global risk assessment
have insulin resistance and its accompanying metabolic risk
factors (the metabolic syndrome). The components of this
syndrome include the atherogenic lipoprotein phenotype (el-
evated triglycerides, small LDL particles, and low HDL-C
levels) (78,86), elevated blood pressure, a prothrombotic
state, and often, impaired fasting glucose (87). The metabolic
syndrome is a clinical diagnosis, but the risk accompanying it
can be assessed in large part by Framingham scoring. This
scoring does not count impaired fasting glucose as an
independent risk factor, although Framingham publications
(88–90) would support doing so. Insulin resistance can be
assumed to be present in a patient with obesity (BMI .30
kg/m2) (46,47) or overweight (BMI 25 to 29.9 kg/m2) plus
abdominal obesity (46,47), especially when accompanied by
elevated plasma triglycerides (78,91), low HDL-C (92), or
impaired fasting glucose (93). Insulin resistance is acquired
largely through obesity and physical inactivity, although a
genetic component undoubtedly exists. The only therapies
presently available for insulin resistance for patients without
diabetes are weight reduction (94) and increased physical
activity (95).
Homocysteine
A high serum concentration of homocysteine is associated
with increased risk for CHD (96–98). The AHA recently
published an advisory on homocysteine that provides an
in-depth review of the relation between homocysteine and
CVD (99). Several mechanisms whereby elevated homocys-
teine predisposes to CVD have been postulated. However, it
remains to be proved in controlled clinical trials that a
reduction in serum homocysteine levels will reduce risk for
CHD. In some patients, nonetheless, high levels of homocys-
teine can be lowered by recommended daily intake of folic
acid (99–101). If homocysteine levels are elevated, patients
should be encouraged to consume the recommended daily
intake of folic acid, as well as vitamins B6 and B12. Routine
measurement of homocysteine levels was not recommended
for purposes of risk assessment, but measurement is optimal
in high-risk patients (99).
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Other Risk Correlates
Other potential risk factors include elevated concentrations of
lipoprotein(a), fibrinogen, and C-reactive protein. Routine
measures of these risk factors currently are not recommended.
An elevated serum lipoprotein(a) correlates with a higher
incidence of CHD in some studies (102,103) but not in others
(104,105). Furthermore, specific therapeutics to reduce li-
poprotein(a) levels are not available; some investigators have
suggested that an elevated lipoprotein(a) level justifies a more
aggressive lowering of LDL-C. An elevated fibrinogen level
also is correlated with a higher CHD incidence (106,107).
Again, no specific therapies are available, except that in
smokers, smoking cessation may reduce fibrinogen concen-
trations (108). Finally, C-reactive protein is promising as a
risk predictor (109,110). The preferred method for measure-
ment appears to be a high-sensitivity test (111). C-reactive
protein appears to be related to systemic inflammation;
however, its causative role in atherogenesis is uncertain.
Implications for Clinical Risk Reduction
Identification of risk factors lies at the heart of clinical efforts
to reduce risk for CVD and/or CHD. Every major risk factor
predisposes to CHD and other cardiovascular events, partic-
ularly if left unattended for long periods. In addition, when
multiple risk factors occur in a single individual, risk is
compounded, which justifies efforts to estimate global risk.
The summation of contributions of individual risk factors can
be a valuable first step in planning a risk-reduction strategy
for individual patients. This first step should be divided into
2 phases. First, absolute risk should be estimated from the
major risk factors (listed in Table 1). Framingham risk
scoring provides an acceptable tool for most non-Hispanic
white, Hispanic, and black Americans. People of South Asian
origin appear to have about twice the absolute risk for any set
of risk factors as whites. In contrast, East Asian Americans
may have a lower absolute risk than other ethnic groups in the
United States. Second, when absolute risk has been estimated
from the major risk factors, consideration can be given to
modifying the estimate in the presence of other risk factors
(Table 2). Clinical judgment is required to estimate incremen-
tal risk incurred by these latter factors. Risk estimates are
useful both for short-term, high-risk primary prevention and
for long-term (or lifetime) primary prevention. Implications
for global risk assessment can be considered for each.
Short-Term Prevention
Recent clinical trials demonstrate that significant risk reduc-
tion can be achieved by aggressive reduction of risk factors in
high-risk patients. Clinical trials have shown that excess risk
can be reduced by ’33% to ’50% in ’5 years. This is
particularly the case when risk-reduction strategies use smok-
ing cessation, blood pressure–lowering agents, cholesterol-
lowering drugs, and aspirin. Clinical trials strongly suggest
that glucose control reduces the incidence of various cardio-
vascular end points in patients with either type 1 diabetes
(112) or type 2 diabetes (113). Other clinical trials (114,115)
strongly suggest that aggressive LDL-lowering therapy re-
duces risk for CHD in patients with type 2 diabetes. For this
reason, detection of patients at high risk, with the aid of
global risk assessment, should be an important aim of routine
medical evaluation of all patients. Specific therapies for risk
reduction in high-risk patients are described in the NCEP
ATP II report for cholesterol management (6), the JNC VI
report for treatment of hypertension (7), and by the ADA’s
guidelines for treatment of diabetes mellitus (8). Once appro-
priate therapies are selected, global risk scores can also be
used to help instruct patients and to improve compliance with
preventive interventions.
Long-Term Prevention
Global risk assessment is particularly useful in young and
middle-aged adults for assessing relative risk and absolute
long-term risk (Figures 1 and 2). Even though short-term risk
may not be high in younger patients who have multiple risk
factors of only moderate severity, long-term risk can be
unacceptably high. Risk assessment in these patients will
highlight the need for early and prolonged intervention on
risk factors. In young adults, relative risk ratios help to reveal
long-term risk for CHD. Although long-term prevention may
not call for the use of risk-reducing drugs, it definitely will
require the introduction of lifestyle modification (ie, smoking
cessation in smokers, weight control, increased physical
activity, and a diet low in cholesterol and cholesterol-raising
fats). The AHA provides guidelines to assist healthcare
professionals in the implementation of life-habit modifica-
tions (30). There is a common misconception that most of the
excess risk accumulated over many years can be erased by
aggressive short-term prevention introduced later in life.
Although the use of risk-reducing drugs can significantly
lower risk when begun in later years, there is no evidence that
it can return a patient to the low-risk status of a younger
person. This reduction can only be accomplished by decreas-
ing the magnitude of coronary plaque burden through long-
term control of risk factors. Therefore, appropriate interven-
tion, guided by risk assessment that is performed periodically
in early adulthood and early middle age, has the potential to
bring about a significant reduction in long-term risk.
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